Equities

Medikit Co Ltd

MKCLF:PNK

Medikit Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Medikit Co Ltd had relatively flat revenues (21.61bn to 21.85bn), though the company grew net income 7.15% from 2.86bn to 3.07bn. A reduction in the cost of goods sold as a percentage of sales from 61.50% to 59.94% was a component in the net income growth despite flat revenues.
Gross margin38.75%
Net profit margin13.58%
Operating margin20.70%
Return on assets5.69%
Return on equity6.56%
Return on investment6.40%
More ▼

Cash flow in JPYView more

In 2024, Medikit Co Ltd increased its cash reserves by 8.63%, or 1.52bn. The company earned 4.83bn from its operations for a Cash Flow Margin of 22.13%. In addition the company generated 3.23bn cash from investing, though they paid out 6.58bn more in financing than they received.
Cash flow per share288.48
Price/Cash flow per share11.76
Book value per share3,015.35
Tangible book value per share2,787.61
More ▼

Balance sheet in JPYView more

Medikit Co Ltd appears to have little financial risk because it is not leveraged and holds substantial cash reserves. However, it has been consistently spending these reserves during the last four years, possibly to shareholders in the form of dividends.
Current ratio5.45
Quick ratio4.77
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in JPY

SmartText is unavailable
Div yield(5 year avg)2.20%
Div growth rate (5 year)12.20%
Payout ratio (TTM)44.00%
EPS growth(5 years)4.34
EPS (TTM) vs
TTM 1 year ago
10.90
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.